D. E. Shaw & Co., Inc. Eagle Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 171,008 shares of EGRX stock, worth $365,957. This represents 0.0% of its overall portfolio holdings.

Number of Shares

171,008

Previous 219,811 22.2%

Holding current value

$365,957

Previous $1.15 Million 16.85%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.34 - $5.6 $163,002 - $273,296	-48,803 Reduced 22.2%	171,008 $957,000
Q1 2024 May 15, 2024	BUY	$4.26 - $6.51 $239,927 - $366,649	56,321 Added 34.45%	219,811 $1.15 Million
Q4 2023 Feb 14, 2024	BUY	$4.63 - $15.21 $247,658 - $813,582	53,490 Added 48.63%	163,490 $855,000
Q3 2023 Nov 14, 2023	SELL	$15.21 - $22.88 $267,376 - $402,207	-17,579 Reduced 13.78%	110,000 $1.73 Million
Q2 2023 Aug 14, 2023	BUY	$17.74 - $31.87 $703,124 - $1.26 Million	39,635 Added 45.07%	127,579 $2.48 Million
Q1 2023 May 15, 2023	BUY	$25.06 - $34.09 $827,656 - $1.13 Million	33,027 Added 60.14%	87,944 $2.49 Million
Q4 2022 Feb 14, 2023	BUY	$24.98 - $39.77 $25,554 - $40,684	1,023 Added 1.9%	54,917 $1.61 Million
Q3 2022 Nov 14, 2022	SELL	$26.42 - $47.12 $1.16 Million - $2.07 Million	-43,970 Reduced 44.93%	53,894 $1.42 Million
Q2 2022 Aug 15, 2022	SELL	$41.26 - $51.35 $734,964 - $914,697	-17,813 Reduced 15.4%	97,864 $4.35 Million
Q1 2022 May 16, 2022	BUY	$44.58 - $52.6 $1.11 Million - $1.31 Million	24,978 Added 27.54%	115,677 $5.73 Million
Q4 2021 Feb 14, 2022	SELL	$45.82 - $56.9 $64,331 - $79,887	-1,404 Reduced 1.52%	90,699 $4.62 Million
Q3 2021 Nov 15, 2021	SELL	$43.79 - $55.78 $1.44 Million - $1.83 Million	-32,865 Reduced 26.3%	92,103 $5.14 Million
Q2 2021 Aug 16, 2021	BUY	$36.86 - $44.5 $619,506 - $747,911	16,807 Added 15.54%	124,968 $5.35 Million
Q1 2021 May 17, 2021	BUY	$40.32 - $50.97 $1.98 Million - $2.51 Million	49,174 Added 83.36%	108,161 $4.51 Million
Q4 2020 Feb 16, 2021	BUY	$41.72 - $51.34 $1.2 Million - $1.48 Million	28,861 Added 95.8%	58,987 $2.75 Million
Q3 2020 Nov 16, 2020	SELL	$37.02 - $51.28 $1.48 Million - $2.06 Million	-40,113 Reduced 57.11%	30,126 $1.28 Million
Q2 2020 Aug 14, 2020	SELL	$43.24 - $55.02 $225,064 - $286,379	-5,205 Reduced 6.9%	70,239 $3.37 Million
Q1 2020 May 15, 2020	BUY	$34.37 - $60.07 $139,267 - $243,403	4,052 Added 5.68%	75,444 $3.47 Million
Q4 2019 Feb 14, 2020	SELL	$54.32 - $64.31 $889,978 - $1.05 Million	-16,384 Reduced 18.67%	71,392 $4.29 Million
Q3 2019 Nov 14, 2019	SELL	$53.25 - $59.98 $1.6 Million - $1.8 Million	-29,984 Reduced 25.46%	87,776 $4.97 Million
Q2 2019 Aug 14, 2019	SELL	$46.61 - $58.45 $3.92 Million - $4.92 Million	-84,147 Reduced 41.68%	117,760 $6.56 Million
Q1 2019 May 15, 2019	SELL	$38.66 - $51.82 $3.22 Million - $4.32 Million	-83,411 Reduced 29.23%	201,907 $10.2 Million
Q4 2018 Feb 14, 2019	BUY	$36.72 - $67.73 $5.75 Million - $10.6 Million	156,499 Added 121.49%	285,318 $11.5 Million
Q3 2018 Nov 14, 2018	BUY	$66.65 - $83.86 $3.22 Million - $4.05 Million	48,344 Added 60.07%	128,819 $8.93 Million
Q2 2018 Aug 14, 2018	BUY	$51.25 - $76.62 $128,791 - $192,546	2,513 Added 3.22%	80,475 $6.09 Million
Q1 2018 May 15, 2018	BUY	$52.16 - $66.86 $1.91 Million - $2.44 Million	36,534 Added 88.19%	77,962 $4.11 Million
Q4 2017 Feb 14, 2018	BUY	$49.6 - $60.87 $2.05 Million - $2.52 Million	41,428	41,428 $2.21 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

9.89M

Call Options Held

1.01M

Put Options Held

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $27.9M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account